0001613103Medtronic plcD02 XH02false00016131032021-05-272021-05-270001613103us-gaap:CommonStockMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2022Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20230.375PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2023Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2025Member2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2025Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2027Member2021-05-272021-05-270001613103mdt:A2020SeniorNotesDue2028Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20311.625PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20311.00PercentMember2021-05-272021-05-270001613103mdt:A2020SeniorNotesDue2032Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20392.250PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20391.50PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2040Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2049Member2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2050Member2021-05-272021-05-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
 _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2021
 _____________________________ 
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
  _____________________________ 
 
Ireland   1-36820   98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices) (Zip Code)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))













Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange
0.00% Senior Notes due 2022 MDT/22B New York Stock Exchange
0.375% Senior Notes due 2023 MDT/23B New York Stock Exchange
0.000% Senior Notes due 2023 MDT/23C New York Stock Exchange
0.25% Senior Notes due 2025 MDT/25 New York Stock Exchange
0.000% Senior Notes due 2025 MDT/25A New York Stock Exchange
1.125% Senior Notes due 2027 MDT/27 New York Stock Exchange
0.375% Senior Notes due 2028 MDT/28 New York Stock Exchange
1.625% Senior Notes due 2031 MDT/31 New York Stock Exchange
1.00% Senior Notes due 2031 MDT/31A New York Stock Exchange
0.750% Senior Notes due 2032 MDT/32 New York Stock Exchange
2.250% Senior Notes due 2039 MDT/39A New York Stock Exchange
1.50% Senior Notes due 2039 MDT/39B New York Stock Exchange
1.375% Senior Notes due 2040 MDT/40A New York Stock Exchange
1.75% Senior Notes due 2049 MDT/49 New York Stock Exchange
1.625% Senior Notes due 2050 MDT/50 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 2.02. Results of Operations and Financial Condition

On May 27, 2021, Medtronic plc (the "Company") issued a press release announcing its fourth quarter and full fiscal year 2021 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
 
Item 9.01.       Exhibits.

(d) List of Exhibits
Exhibit Number    Description
  
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).








SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
      MEDTRONIC PUBLIC LIMITED COMPANY
Date: May 27, 2021     By   /s/ Karen L. Parkhill
      Karen L. Parkhill
      Executive Vice President and Chief Financial Officer







EXHIBIT INDEX

Exhibit Number    Description
  
104
Cover Page Interactive Data File (embedded with the Inline XBRL document).



Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Medtronic Charts.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Medtronic Charts.